

EXPRESS MAIL NO. EV336654351US

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 980034.417C1	APPLICATION NO. 09/960,264
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Ronald Berenson et al.	
		FILING DATE September 20, 2001	GROUP ART UNIT 1651

APR 21 2004

## U.S. PATENT DOCUMENTS

*EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
b	AA 5,443,983	08/22/95	Ochoa et al.	435	240.2	
	AB 5,470,730	11/28/95	Greenberg et al.	435	172.3	
	AC 5,674,704	10/07/97	Goodwin et al.	435	69.1	
	AD 5,804,442	09/08/98	Romet-Lemonne et al.	435	374	
	AE 6,113,901	09/05/00	Bluestone	424	154.1	
	AF 6,143,297	11/07/00	Bluestone	424	184.1	
	AG 6,129,916	10/10/00	Chang	424	179.1	
	AH 6,197,298	03/06/01	Chang	424	179.1	
	AI 6,316,257	11/13/01	Flyer et al.	435	372.3	
✓	AJ 6,355,779	03/12/02	Goodwin et al.	530	388.23	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
✓	AK	EP 633930 B1	04/26/00	EPO		
↓	AL	WO 97/05233	02/13/97	WIPO		
	AM	WO 97/05239	02/13/97	WIPO		
↓	AN	WO 03/024312	03/27/03	WIPO		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	AO	Baroja, M.L. et al., "The Anti-T Cell Monoclonal Antibody 9.3 (Anti-CD28) Provides a Helper Signal and Bypasses the Need for Accessory Cells in T Cell Activation with Immobilized Anti-CD3 and Mitogens," <i>Cellular Immunology</i> 120: 205-217, 1989.
	AP	Bergstresser, P.R. et al., "T Cell-Mediated Terminal Maturation of Dendritic Cells," in <i>Dendritic Cell in Fundamental and Clinical Immunology</i> , Ricciardi-Castagnoli (Ed.), Plenum Press, New York, 1997, pgs. 65-69.
↓	AQ	Groh, V. et al., "Stimulation of T Cell Autoreactivity by Anomalous Expression of NKG2D and its MIC Ligands in Rheumatoid Arthritis," <i>Proceedings of the National Academy of Sciences</i> 100(16): 9452-9457, August 5, 2003.

EXAMINER	LANKFORD	DATE CONSIDERED
*		5/25/04

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.417C1	APPLICATION NO. 09/960,264
<b>FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APR 11 2004 U.S. PATENT AND TRADEMARK OFFICE			
		APPLICANTS Ronald Berenson et al.			
		FILING DATE September 20, 2001	GROUP ART UNIT 1651		

**U.S. PATENT DOCUMENTS**

*EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BL	BA 6,544,788	04/08/03	Singh	435	383	
	BB 2001/0031253	10/18/01	Gruenberg	424	93.1	
	BC 2002/0090362	07/11/02	Strauss	424	93.21	
	BD 2002/0182730	12/05/02	Gruenberg	435	375	
	BE 2003/0039650	02/27/03	Gruenberg	424	144.1	
	BF 2003/0134341	07/17/03	Gruenberg	435	7.21	
	BG 2003/0134415	07/17/03	Gruenberg	435	372	
	BH 2003/0170238	09/11/03	Gruenberg	424	144.1	
	BI 2003/0175242	09/18/03	Gruenberg	424	93.2	
↓	BJ 2003/0175272	09/18/03	Gruenberg	424	144.1	

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
BL	BK WO 03/025158	03/27/03	WIPO		
	BL WO 03/034820	05/01/03	WIPO		
	BM WO 03/043643	05/30/03	WIPO		
↓	BN WO 03/077658	09/25/03	WIPO		

**OTHER PRIOR ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

BL	BO	Lanzavecchia, A., "The Role of Dendritic Cells in the Generation of Effector and Memory T Cell Responses," from <i>The Midwinter Conference of Immunologists</i> , January 22-25, 2000, available at <a href="http://www.midwconfimmunol.org/Midwinter00/sessions/lanzavecchia.html">www.midwconfimmunol.org/Midwinter00/sessions/lanzavecchia.html</a> .
	BP	Li, Q. et al., "Expanded Tumor-reactive CD4 <sup>+</sup> T-Cell Responses to Human Cancers Induced by Secondary Anti-CD3/Anti-CD28 Activation," <i>Clinical Cancer Research</i> 5: 461-469, February 1999.
↓	BQ	Li, Q. et al., "Immunological Effects of BCG as an Adjuvant in Autologous Tumor Vaccines," <i>Clinical Immunology</i> 94(1): 64-72, January 2000.

EXAMINER	LANKFORD	DATE CONSIDERED
5/25/4		

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

EXPRESS MAIL NO. EV336654351US

Sheet 3 of 3

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.417C1	APPLICATION NO. 09/960,264
<b>FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APPLICANTS Ronald Berenson et al.			
		FILING DATE September 20, 2001	GROUP ART UNIT 1651	APR 21 2004 U.S. PATENT & TRADEMARK OFFICE	

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LBL	CA	2003/0194395	10/16/03	Gruenberg et al.	424	93.7	
	CB						
	CC						
	CD						
	CE						
	CF						
	CG						
	CH						
	CI						
	CJ						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES      NO
	CK				
	CL				
	CM				
	CN				
	CO				

**OTHER PRIOR ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

LBL	CP	Zou, J.-P. et al., "Tumor-Bearing Mice Exhibit A Progressive Increase in Tumor Antigen-Presenting Cell Function and A Reciprocal Decrease in Tumor Antigen-Responsive CD4 <sup>+</sup> T Cell Activity," <i>The Journal of Immunology</i> 148(2): 648-655, January 15, 1992.
	CQ	
	CR	

EXAMINER	LANKFORD	DATE CONSIDERED
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).		